Echocardiographic haemodynamic monitoring in the context of HeartMate 3™ therapy: a systematic review

• Published in: ESC Heart Failure 2024-08, Vol.11 (4), p.2033-2042
• Main Authors: Ohlsson, Linus, Papageorgiou, Joanna‐Maria, Ebbers, Tino, Aneq, Meriam Åström, Tamás, Éva, Granfeldt, Hans
• Format: Article
• Language: English
• Subjects: Blood clots; Cohort analysis; Content analysis; Cross-sectional studies; Echocardiography; Echocardiography - methods; FDA approval; Haemodynamic monitoring; Heart failure; Heart Failure - epidemiology; Heart Failure - physiopathology; Heart Failure - therapy; Heart-Assist Devices; HeartMate 3; Hemodynamic Monitoring - methods; Hemodynamics; Hemodynamics - physiology; Humans; LVAD; MCS; Original; Transplants & implants; Ultrasonic imaging
• ISSN: 2055-5822; 2055-5822
• DOI: 10.1002/ehf2.14759

Aims While echocardiography remains essential within haemodynamic monitoring of durable mechanical circulatory support, previous echocardiographic guidelines are missing scientific evidence for the novel HeartMate 3™ (HM3) system. Accordingly, this review aims to summarize available echocardiographic evidence including HM3. Methods and results This systematic review adhered to the PRISMA 2020 guidelines. Searches were conducted during August 2023 across PubMed, Embase, and Google Scholar using specific echocardiographic terms combined with system identifiers. Study quality was assessed using the Newcastle–Ottawa Scale (NOS) for cohort studies and Critical Appraisal Instrument (PCAI) for cross‐sectional studies. Nine studies met the inclusion criteria, of which eight cohort studies and one cross‐sectional study. Aortic regurgitation (AR) prevalence at approximately 12 months of support exhibited heterogenicity (33.5% (Δ 33%)) in a limited number of studies (n = 3). Several studies (n = 5) demonstrated an increasing prevalence and severity of AR during HM3 support, generating moderate to high level of evidence. One AR study showed a higher cumulative incidence of death and heart failure (HF) readmission compared with those without significant AR, hazard ratio 3.42 (95% CI 1.48–8.76). A second study showed that a worsening AR group had significantly lower survival‐free from HF readmission (59% vs. 89%, P = 0.023) with a hazard ratio of 5.18 (95% CI 1.07–25.0), while a third study did not reveal any differences in cardiac‐related hospitalizations in the 12 months follow‐up or non‐cardiac‐related hospitalization. Mitral regurgitation (MR) prevalence at approximately 12 months of support exhibited good consistency 15.0% (Δ 0.8%) in both included studies, which did not reveal any significant pattern of changing prevalence over time. Tricuspid regurgitation (TR) prevalence at approximately 12 months of support exhibited fair consistency 28.5% (Δ 8.3%) in a limited number of studies (n = 2); both studies showed a statistically un‐confirmed trend of increased TR prevalence over time. The evidence of general prevalence of right ventricular dysfunction (RVD) was insufficient due to lack of studies. Conclusions There are few methodologically consistent studies with focus on long‐term haemodynamic effects. Aortic regurgitation still seems to be a prevalent and potentially significant finding. The available evidence concerning right heart function is limited despite clin